Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Top Cited Papers
Open Access
- 16 February 2006
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 354 (7), 709-718
- https://doi.org/10.1056/nejmoa053007
Abstract
Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity. We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b.Keywords
This publication has 27 references indexed in Scilit:
- A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for MelanomaClinical Cancer Research, 2004
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2001
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin-2 AloneJournal of Immunotherapy, 1995
- Antiphospholipid syndrome associated with immunotherapy for patients with melanomaCancer, 1994
- Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinomaEuropean Journal of Cancer and Clinical Oncology, 1990
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsThe New England Journal of Medicine, 1988